Hir­ing? How End­points can help your com­pa­ny fill open po­si­tions with our tal­ent­ed read­ers

We’ve just launched End­points Ca­reers, our new prod­uct con­nect­ing em­ploy­ers and job­seek­ers. The com­pe­ti­tion for bio­phar­ma tal­ent is fierce, and giv­en the unique place End­points News has in the in­dus­try, we think our ap­proach has a few key ad­van­tages that make this a com­pelling of­fer and not just an­oth­er “job board.”

The first rea­son is that we’re an­chor­ing it to En­ter­prise, our $1,000/year paid sub­scrip­tion plan for com­pa­nies of all sizes. You can think of En­ter­prise as the “com­plete” ver­sion of End­points News. No mat­ter how large or small the com­pa­ny is, that one price un­locks pay­wall con­tent for every em­ploy­ee. No seat li­cens­es or vol­ume pric­ing. We want to make this pro­gram an easy de­ci­sion at every com­pa­ny with an in­ter­est in the bio­phar­ma world. Sev­er­al hun­dred have al­ready joined En­ter­prise, and now with End­points Ca­reers, we want to make it even more ben­e­fi­cial to join.

Start­ing to­day, we’re in­tro­duc­ing a new ben­e­fit for En­ter­prise sub­scribers: Two Fea­tured Job List­ings per year on End­points Ca­reers — an $800 val­ue. If you’re a hir­ing man­ag­er at a com­pa­ny with a valid En­ter­prise sub­scrip­tion, you have two fea­tured job post­ings wait­ing for you to re­deem — just con­tact Tom Kowal­sky tom@end­pointsnews.com on our team to get start­ed. And once you do, the list­ings will be dis­trib­uted across the en­tire End­points net­work: email, web, and so­cial. Again: we’re sell­ing the same pack­age for $800 for com­pa­nies who aren’t part of the En­ter­prise pro­gram.

The oth­er key ad­van­tage on End­points Ca­reers is our fo­cus on qual­i­ty, not quan­ti­ty.

Most “job boards” be­gin with thou­sands of job list­ings pre-filled, in an at­tempt to look busy and gain web traf­fic. We take the op­po­site view. We on­ly want re­cent jobs with the high­est rel­e­vance to our au­di­ence base. And giv­en the big traf­fic num­bers to End­points News and our re­lat­ed dis­tri­b­u­tion chan­nels, we’re able to ad­ver­tise these po­si­tions in a very ef­fec­tive way: Job seek­ers are as­sured of see­ing on­ly the high­est qual­i­ty list­ings from em­ploy­ers, while em­ploy­ers get wide air cov­er­age for their open po­si­tions with­in the elite End­points read­er­ship.

We de­signed it this way. Bio­phar­ma tends to be an in­su­lar crowd with an es­pe­cial­ly big pre­mi­um placed on re­fer­rals from in­side a net­work — which is no sur­prise in an in­dus­try that is as heav­i­ly reg­u­lat­ed and sci­ence-based as this one is. In­sti­tu­tion­al knowl­edge is held by peo­ple, not in com­pa­ny clouds or lab notes. And the net­work ef­fects gained from re­cruit­ing the right kind of ex­pe­ri­enced tal­ent who know the right peo­ple are too valu­able to be mea­sured in dol­lars. This won’t ever change. It’s a sto­ry we chron­i­cle in End­points about every com­pa­ny with am­bi­tion, time and time again.

But re­fer­rals do have their lim­its. Was the job op­por­tu­ni­ty ex­posed to the most di­verse tal­ent pool pos­si­ble? How does a found­ing team of a few fa­mil­iar faces re­cruit a work­force that can bring fresh ideas and ap­proach­es?

Ba­si­cal­ly: Did we cast a wide enough net?

End­points Ca­reers is here to help solve this is­sue: ad­ver­tis­ing bio­phar­ma op­por­tu­ni­ties with­in an elite net­work, and do­ing so on a scale that ex­pos­es it to the broad­est au­di­ence pos­si­ble.

We think that’s a com­pelling of­fer that con­tin­ues to dif­fer­en­ti­ate End­points and how we serve our read­ers. End­points Ca­reers will on­ly con­tin­ue to grow through­out the year as we in­te­grate it with our week­ly Peer Re­view col­umn. If you have any ques­tions or want to get start­ed with End­points Ca­reers, we’ve brought Tom tom@end­pointsnews.comon board as a ded­i­cat­ed client man­ag­er to help, and you can al­ways con­tact me di­rect­ly as well. So please check out End­points Ca­reers — we’re very ex­cit­ed to bring it to you.

– Ar­salan Arif
Founder & CEO, End­points News
aa@end­pointsnews.com

The Price of Re­lief: Ex­plor­ing So­lu­tions to the Ris­ing Costs of On­col­o­gy Drugs

In 2020, The National Cancer Institute estimated about 1.8 million new cases of cancer diagnosed in the United States, while the costs associated with treatment therapies continued to escalate. Given the current legislative climate on drug pricing, it’s never been more important to look at the evolution of drug pricing globally and control concerns of sustainable and affordable treatments in oncology.

Lat­est news on Pfiz­er's $3B+ JAK1 win; Pacts over M&A at #JPM22; 2021 by the num­bers; Bio­gen's Aduhelm reck­on­ing; The sto­ry of sotro­vimab; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

For those of you who attended #JPM22 in any shape or form, we hope you had a fruitful time. Regardless of how you spent the past hectic week, may your weekend be just what you need it to be.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 128,800+ biopharma pros reading Endpoints daily — and it's free.

A $3B+ peak sales win? Pfiz­er thinks so, as FDA of­fers a tardy green light to its JAK1 drug abroc­i­tinib

Back in the fall of 2020, newly crowned Pfizer chief Albert Bourla confidently put their JAK1 inhibitor abrocitinib at the top of the list of blockbuster drugs in the late-stage pipeline with a $3 billion-plus peak sales estimate.

Since then it’s been subjected to serious criticism for the safety warnings associated with the class, held back by a cautious FDA and questioned when researchers rolled out a top-line boast that their heavyweight contender had beaten the champ in the field of atopic dermatitis — Dupixent — in a head-to-head study.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 128,800+ biopharma pros reading Endpoints daily — and it's free.

Robert Califf, FDA commissioner nominee (Graeme Sloan/Sipa USA/Sipa via AP Images)

Rob Califf ad­vances as Biden's FDA nom­i­nee, with a close com­mit­tee vote

Rob Califf’s second confirmation process as FDA commissioner is already much more difficult than his near unanimous confirmation under the Obama administration.

The Senate Health Committee on Thursday voted 13-8 in favor of advancing Califf’s nomination to a full Senate vote. Several Democrats voted against Califf, including Sen. Bernie Sanders and Sen. Maggie Hassan. Several other Democrats who aren’t on the committee, like West Virginia’s Joe Manchin and Ed Markey of Massachusetts, also said Thursday that they would not vote for Califf. Markey, Hassan and Manchin all previously expressed reservations about the prospect of Janet Woodcock as an FDA commissioner nominee too.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 128,800+ biopharma pros reading Endpoints daily — and it's free.

Michel Vounatsos, Biogen CEO (World Economic Forum/Ciaran McCrickard)

Bio­gen vows to fight CM­S' draft cov­er­age de­ci­sion for Aduhelm be­fore April fi­nal­iza­tion

Biogen executives made clear in an investor call Thursday they are not preparing to run a new CMS-approved clinical trial for their controversial Alzheimer’s drug anytime soon.

As requested in a draft national coverage decision from CMS earlier this week, Biogen and other anti-amyloid drugs will need to show “a meaningful improvement in health outcomes” for Alzheimer’s patients in a randomized, placebo-controlled trial to get paid for their drugs, rather than just the reduction in amyloid plaques that won Aduhelm its accelerated approval in June.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 128,800+ biopharma pros reading Endpoints daily — and it's free.

CRO own­er pleads guilty to ob­struct­ing FDA in­ves­ti­ga­tion in­to fal­si­fied clin­i­cal tri­al da­ta

The co-owner of a Florida-based clinical research site pleaded guilty to lying to an FDA investigator during a 2017 inspection, revealing that she falsely portrayed part of a GlaxoSmithKline pediatric asthma study as legitimate, when in fact she knew that certain data had been falsified, the Department of Justice said Wednesday.

Three other employees — Yvelice Villaman Bencosme, Lisett Raventos and Maytee Lledo — previously pleaded guilty and were sentenced in connection with falsifying data associated with the trial at the CRO Unlimited Medical Research.

Susan Galbraith, AstraZeneca EVP, Oncology R&D

Can­cer pow­er­house As­traZeneca rolls the dice on a $75M cash bet on a buzzy up­start in the on­col­o­gy field

After establishing itself in the front ranks of cancer drug developers and marketers, AstraZeneca is putting its scientific shoulder — and a significant amount of cash — behind the wheel of a brash new upstart in the biotech world.

The pharma giant trumpeted news this morning that it is handing over $75 million upfront to ally itself with Scorpion Therapeutics, one of those biotechs that was newly birthed by some top scientific, venture and executive talent and bequeathed with a fortune by way of a bankroll to advance an only hazily explained drug platform. And they are still very much in the discovery and preclinical phase.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 128,800+ biopharma pros reading Endpoints daily — and it's free.

‘Skin­ny la­bels’ on gener­ics can save pa­tients mon­ey, re­search shows, but re­cent court de­ci­sions cloud fu­ture

New research shows how generic drug companies can successfully market a limited number of approved indications for a brand name drug, prior to coming to market for all of the indications. But several recent court decisions have created a layer of uncertainty around these so-called “skinny” labels.

While courts have generally allowed generic manufacturers to use their statutorily permitted skinny-label approvals, last summer, a federal circuit court found that Teva Pharmaceuticals was liable for inducing prescribers and patients to infringe GlaxoSmithKline’s patents through advertising and marketing practices that suggested Teva’s generic, with its skinny label, could be employed for the patented uses.

A patient in Alaska receiving an antibody infusion to prevent Covid hospitalizations in September. All but one of these treatments has been rendered useless by Omicron (Rick Bowmer/AP Images)

How a tiny Swiss lab and two old blood sam­ples cre­at­ed one of the on­ly ef­fec­tive drugs against Omi­cron (and why we have so lit­tle of it)

Exactly a decade before a novel coronavirus broke out in Wuhan, Davide Corti — a newly-minted immunologist with frameless glasses and a quick laugh — walked into a cramped lab on the top floor of an office building two hours outside Zurich. He had only enough money for two technicians and the ceiling was so low in parts that short stature was a job requirement, but Corti believed it’d be enough to test an idea he thought could change medicine.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.